Emory HIV/AIDS Clinical Trials Unit

埃默里艾滋病毒/艾滋病临床试验单位

• 批准号: 7994201
• 负责人: Jeffrey Lennox
• 金额: --
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-01 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7994201
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Accounting; Acquired Immunodeficiency Syndrome; Adult; African American; Agreement; Area; Caring; Cities; Clinic; Clinical Research; Clinical Trials Unit; Communicable Diseases; Country; Doctor of Medicine; Epidemic; Faculty; Female; HIV; HIV Vaccine Trials Network; HIV prevention trials network; HIV vaccine; Hispanics; Leadership; Medical center; Microbicide Trials Network; Minority; National Institute of Allergy and Infectious Disease; Population; Principal Investigator; Reporting; Research; Scientist; Site; Testing; United States; United States Department of Veterans Affairs; Universities; Vaccines; Veterans; Woman; Work; clinical research site; men; metropolitan; microbicide; patient population

DESCRIPTION (provided by applicant): Through this application, NIAID-sponsored clinical research at Emory University will be integrated into the Emory HIV/AIDS Clinical Trials Unit (EHCTU). The EHCTU will perform clinical research trials through prior agreement with the AIDS Clinical Trials Group (ACTG) and the Microbicides Trials Network (MTN). In addition, the EHCTU has the scientific expertise and appropriate patient populations to make important contributions to the HIV Vaccine Trials Network (HVTN), the HIV Prevention Trials Network (HPTM) and the INSIGHT network. Emory scientists currently make important scientific and leadership contributions to each of these networks. Emory University is located in Atlanta, a city at the epicenter of the evolving HIV epidemic in the United States. Of the 101 metropolitan areas with a population greater than 500,000, Atlanta ranked 7th for AIDS reporting in 2003. Atlanta accounts for 67% of Georgia's African-American AIDS cases, 75% of Hispanic cases, and 56% of minority female cases. Emory faculty provides care for about6,000 HIV-infected men and over 1,000 infected women. The EHCTU will consist of an administrative core and three clinical research sites. Jeffrey Lennox, M.D. will be the Principal Investigator for the EHCTU and for the ACTG at Emory. Carlos del Rio, M.D. will be the Principal Investigator for the HPTN trials. The Ponce de Leon Center, where over 4,000 HIV-infected adults are in care, will be the research site for the ACTG and HPTN. Francis Priddy, M.D. will be the Principal Investigator for the HVTN and MTN trials. These trials will be done at the Hope Clinic of the Emory Vaccine Center, one of the leading HIV vaccine and microbicides testing sites in the United States. David Rimland, M.D. will be the Principal Investigator for the INSIGHT trials. These trials will be performed at the Atlanta Veterans Administration Medical Center, which has the largest population of HIV-infected veterans in the country. Dr's Lennox, del Rio, Priddy and Rimland are all faculty in the Division of Infectious Diseases, have an excellent working relationship and a demonstrated record of collaborative clinical research accomplishments. ADMINISTRATIVE COMPONENT:

描述（由申请人提供）：通过此申请，niaid资助的埃默里大学的临床研究将被纳入埃默里艾滋病毒/艾滋病临床试验单位（EHCTU）。EHCTU将通过事先与艾滋病临床试验组（ACTG）和杀微生物剂试验网络（MTN）达成的协议进行临床研究试验。此外，EHCTU拥有科学专业知识和适当的患者群体，可以为艾滋病毒疫苗试验网络（HVTN）、艾滋病毒预防试验网络（HPTM）和INSIGHT网络做出重要贡献。埃默里大学的科学家们目前为这些网络做出了重要的科学和领导贡献。埃默里大学位于美国艾滋病流行的中心城市亚特兰大。2003年，在101个人口超过50万的大都市区中，亚特兰大的艾滋病报告率排名第七。亚特兰大占佐治亚州非洲裔艾滋病病例的67%，西班牙裔病例的75%，少数族裔女性病例的56%。埃默里大学的教职员工为大约6000名感染艾滋病毒的男性和1000多名感染艾滋病毒的女性提供护理。EHCTU将由一个行政中心和三个临床研究中心组成。医学博士Jeffrey Lennox将担任EHCTU和Emory ACTG的首席研究员。医学博士Carlos del bb0将是HPTN试验的首席研究员。庞塞德莱昂中心将成为ACTG和HPTN的研究地点，这里有4000多名感染艾滋病毒的成年人在接受治疗。Francis Priddy医学博士将担任HVTN和MTN试验的首席研究员。这些试验将在埃默里疫苗中心的希望诊所进行，该中心是美国领先的艾滋病毒疫苗和杀微生物剂测试地点之一。医学博士David Rimland将担任INSIGHT试验的首席研究员。这些试验将在亚特兰大退伍军人管理医疗中心进行，该中心是美国感染艾滋病毒的退伍军人人数最多的地方。博士的Lennox， del b里约热内卢，Priddy和Rimland都是传染病部的教员，他们有着良好的工作关系，并在合作临床研究方面取得了骄人的成绩。